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Disord. 2013;17:410-419.The European ADHD Guidelines Group replies:r. Micoulaud-Franchi et al. raise concerns relating to
our 2016 meta-analysis1 of neurofeedback as aD treatment for attention-deﬁcit/hyperactivity disor-
der (ADHD). It is encouraging that Dr. Micoulaud-Franchi
et al. agree with us that there is “an urgent need to
conduct future research that associates both high quality of
[randomized controlled trial] RCT and high quality of
[electroencephalography] EEG-neurofeedback sessions.”
Consistent with this, we wrote, “Future efforts should focus
on implementing standard neurofeedback protocols,
ensuring learning, and optimizing clinically relevant trans-
fer.”1(p444) This is in line with the signiﬁcant advantage for
neurofeedback demonstrated in our additional preliminary
analysis of the few studies meeting such standards.
Dr. Micoulaud-Franchi et al. are primarily concerned
about the discrepancy between Cortese et al.1 and a previous
meta-analysis (Micoulaud-Franchi et al.2), which they argue
is surprising, because, in their view, the 2 meta-analyses
were essentially based on the same core methodology and
the same trials. In response, we would like to make the
following points.
1. Do Micoulaud-Franchi et al.2 and Cortese et al.1 reach
different conclusions? The ﬁndings of the 2 meta-analyses
are substantially similar. Neurofeedback was reported
as superior for all most proximal outcomes but not for
probably blinded total ADHD or hyperactive impulsive
symptoms. The only way the 2 articles differed statisti-
cally was that Micoulaud-Franchi et al.2 found greater
neurofeedback efﬁcacy for probably blinded measures of
inattention, whereas Cortese et al.1 did not.
2. Did Micoulaud-Franchi et al.2 and Cortese et al.1 use the same
methodology and include the same trials? Micoulaud-Franchi
et al.2 claim that the 2 meta-analyses had the same1092 www.jaacap.orgmethodology. Indeed, the 2 meta-analyses adopted the
distinction between probably blinded and most proximal
outcomes, ﬁrst introduced in our 2012 protocol (European
ADHD Guidelines Group, PROSPERO CRD42011001393)
as a way to deal with the thorny issue of non-blinding of
outcomes in nonpharmacologic treatment trials.3 Leaving
this aside, however, Micoulaud-Franchi et al.2 and Cor-
tese et al.1 had different trial inclusion criteria. This ex-
plains why Micoulaud-Franchi et al.2 included 5 trials,
whereas Cortese et al.1 included 13. First, in Cortese et al.,1
extending our original 2012 protocol,3 we removed the
mandatory requirement for studies to have ADHD
symptoms-related outcomes. Second, Micoulaud-Franchi
et al.2 excluded studies in which “treatment as usual” or
waitlist was the control, which Cortese et al.1 did not.
Third, Cortese et al.1 allowed studies in which partici-
pants met validated cutoffs on standard ADHD scales to
be included, whereas Micoulaud-Franchi et al.2 included
studies only if participants had a full ADHD diagnosis.
Furthermore, Cortese et al.1 also included data from the
2015 report by Bink et al.4 and obtained additional un-
published data from Christiansen et al.,5 which extended
a preliminary report published in 2013. These data were
not available to Micoulad-Franchi et al.2
3. Did Cortese et al.1 make correct selections of probably blin-
ded measures? Micoulad-Franchi et al. see the choice of
the Behavioral Observation of Students in Schools
(BOSS) observational measure as the best probably
blinded outcome from Steiner et al.6 as a mistake. This
choice was, in fact, dictated by our protocol, in which
direct observation by trained, blinded raters trump
adult-rated measures (whether parent or teacher). This
rule was introduced to remove, wherever possible, the
practically inevitable confound between teacher versus
parent ratings and situation (home versus school),
because direct observation is not tied to a particular
setting. Furthermore, although Micoulaud-Franchi et al.
are concerned that the BOSS was not completed by
blinded raters, Steiner et al.6 stated explicitly that it was
(page 20). In this case, the BOSS was without doubt
superior to teacher ratings as a probably blinded mea-
sure, because the latter were almost certainly aware of
treatment allocation. The other option is to remove the
study by Steiner et al.6 from the “probably blinded”
analysis. Doing this retrospectively did not change the
results regarding inattention (standard mean difference
0.22, 95% CI –0.04–0.47).
Taking points 2 and 3 together, we would argue that the
differences between Cortese et al.1 and Micoulaud-Franchi
et al.2 are due to a combination of different rules for trial
inclusion and probably blinded outcome selection.
Micoulaud-Franchi et al. also suggest that we should have
removed the study by Arnold et al.,7 which they consider
ﬂawed in a number of ways, although according to our
assessment using the Cochrane approach, the risk of bias
was uncertain or low. In a sense, we have already addressed
this point through our sensitivity analysis excluding ran-
domized controlled trials that used what we deemedJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
VOLUME 55 NUMBER 12 DECEMBER 2016
LETTERS TO THE EDITORnonstandard neurofeedback approaches (including Arnold
et al.7) that produced more promising, albeit more tentative,
results. We also ran a sensitivity analysis removing only the
study by Arnold et al. This did not affect the results (data
available on request).
In sum, it goes without saying that neither the
Micoulaud-Franchi et al.2 nor our meta-analysis should be
seen as deﬁnitive—rather, it provides a stimulus for thera-
peutic innovation and improvement and better-quality trials.
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